Real-time enrollment status for this psma-positive metastatic castration resistant prostate cancer (mcrpc) with prior exposure to one prior arpi who are candidates for taxane-based chemotherapy clinical trial
Current Status
Recruiting
Checked: August 28, 2026 at 9:51 PM UTC
| NCT Number | NCT07226986 |
| Recruiting Status | Recruiting |
| Condition | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy |
| Phase | PHASE1 |
| Target Enrollment | 123 participants |
| Active Locations | 3 sites in the US |
| Sponsor | Novartis Pharmaceuticals |
| Last Updated on CT.gov | August 18, 2026 (1 week ago) |
As of August 28, 2026: Clinical trial NCT07226986 is currently recruiting participants. This phase1 study for psma-positive metastatic castration resistant prostate cancer (mcrpc) with prior exposure to one prior arpi who are candidates for taxane-based chemotherapy is actively seeking new participants at 3 locations across the United States. The study is sponsored by Novartis Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07226986 is actively recruiting participants as of August 28, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 3 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07226986 was last updated 1 week ago (August 18, 2026). HelloStudys verifies this status automatically.